$1.12
(Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-27
-
Face value
--
-
Shares outstanding
1,822,820
6 Years Aggregate
CFO
$-457.05 Mln
EBITDA
$-494.42 Mln
Net Profit
$-503.20 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Talis Biomedical Corp (TLIS)
| -- | -- | -- | -- | -27.2 | -57.0 | -- |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Talis Biomedical Corp (TLIS)
| 11.4 | -88.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Talis Biomedical Corp (TLIS)
|
2.8 | 5.2 | 0.3 | -51.0 | -18,410.0 | -86.7 | -- | 0.1 |
| 78.0 | 11,082.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 49.5 | 18.5 | |
| 46.2 | 12,241.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.2 | |
| 92.3 | 12,229.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.2 | 7,860.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25.9 | 156.7 | |
| 296.7 | 8,519.4 | 389.1 | 204.8 | 41.5 | 18.9 | 38.7 | 6.6 | |
| 534.9 | 12,443.8 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 428.7 | 12,189.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.9 | 19.9 | |
| 102.4 | 8,234.3 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 333.3 | 9,422.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.7 |
Shareholding Pattern
View DetailsAbout Talis Biomedical Corp (TLIS)
Talis Biomedical Corporation does not have significant operations. Previously, it was involved in the development of medical devices for infectious diseases and other conditions at the point of care in the United States. The company evaluates... strategic alternatives, including acquisition, merger, reverse merger, divestiture of assets, a voluntary reorganization, dissolution or liquidation, and licensing or other strategic transactions. Talis Biomedical Corporation was incorporated in 2013 and is based in Chicago, Illinois. Read more
-
CEO & Director
Mr. Robert Kelley MBA
-
CEO & Director
Mr. Robert Kelley MBA
-
Headquarters
Chicago, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Talis Biomedical Corp (TLIS)
What is the current share price of Talis Biomedical Corp (TLIS) Today?
The share price of Talis Biomedical Corp (TLIS) is $2.84 (NASDAQ) as of 02-Apr-2026 09:30 EDT. Talis Biomedical Corp (TLIS) has given a return of -27.16% in the last 3 years.
What is the current PB & PE ratio of Talis Biomedical Corp (TLIS)?
Since, TTM earnings of Talis Biomedical Corp (TLIS) is negative, P/E ratio is not available.
The P/B ratio of Talis Biomedical Corp (TLIS) is 0.11 times as on 02-Apr-2026, a 98 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.25
|
0.23
|
|
2022
|
-0.01
|
0.01
|
|
2021
|
-0.04
|
0.03
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of Talis Biomedical Corp (TLIS)?
The 52-week high and low of Talis Biomedical Corp (TLIS) are Rs 2.84 and Rs 2.84 as of 08-May-2026.
What is the market cap of Talis Biomedical Corp (TLIS)?
Talis Biomedical Corp (TLIS) has a market capitalisation of $ 5 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Talis Biomedical Corp (TLIS)?
Before investing in Talis Biomedical Corp (TLIS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.